drugset
drugset / Trial / NCT05446870

Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)

NCT05446870 ↗

Phase 2 Completed 160 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective is to evaluate in participants with high-grade serous ovarian cancer (HGSOC), whether the reduction from baseline in circulating tumor deoxyribonucleic acid (ctDNA) at Cycle 3 (ΔctDNA) is larger in participants receiving MK-4830 + pembrolizumab in combination with standard of care (SOC) therapy than in those receiving pembrolizumab + SOC therapy.

Timeline

Start
2022-07-25
Primary completion
2023-12-20
Completion
2024-10-16

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-4830 Unknown 800 mg Intravenous
Background Bevacizumab Monoclonal antibody — —
Background Carboplatin Small molecule 5 unknown Intravenous
Background Carboplatin Small molecule 6 unknown Intravenous
Background Docetaxel Small molecule 75 mg/m2 Intravenous
Background Paclitaxel Small molecule 175 mg/m2 Intravenous
Background Pembrolizumab Monoclonal antibody 200 mg Intravenous

Indications

ovarian serous adenocarcinoma